Itulazax

Betula verrucosa, the active ingredient in Itulazax, is a allergen immunotherapy presented as a sublingual preparation for sublingual use. It treats seasonal allergic rhinitis caused by birch pollen in patients with documented sensitivity.

GNH USA supplies Itulazax as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Itulazax is used in allergen immunotherapy to address birch pollen‑induced seasonal allergic rhinitis.

Seasonal allergic rhinitis (birch pollen): reduces nasal congestion, sneezing, and itching by inducing immune tolerance.

Adverse reactions to Itulazax are generally mild, but patients should be aware of possible side effects.

Common Side Effects: - Mild oral itching: transient irritation under the tongue - Transient throat irritation: mild soreness after dosing - Mild nasal congestion: temporary stuffiness

Serious or Rare Side Effects: - Anaphylaxis: severe systemic allergic reaction requiring emergency care - Angioedema: swelling of lips, tongue or airway - Severe asthma exacerbation: sudden worsening of breathing

Before prescribing Itulazax, clinicians should consider the following precautions. - Assess allergy history: confirm birch pollen sensitivity with skin test or specific IgE. - Monitor during first administrations: observe for systemic reactions for at least 30 minutes. - Avoid use in uncontrolled asthma: risk of severe respiratory events. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Concomitant immunotherapy: do not combine with other allergen extracts without specialist advice. - Store below 25°C: keep in original container, protect from moisture and direct sunlight.

Itulazax may interact with other medications or substances as follows.

Major Interactions (Avoid): - Beta‑blockers: may mask symptoms of anaphylaxis and hinder treatment. - ACE inhibitors: increase risk of angioedema when combined with allergen exposure.

Moderate Interactions (Monitor Closely): - Antihistamines: may reduce perceived efficacy; timing of dose may need adjustment. - Corticosteroids: concurrent use may alter immune response; monitor clinical outcome. - Other allergen immunotherapies: overlapping exposure may increase systemic reaction risk.